Researchers in Prof. Mark Kay's laboratory have developed variant AAV (adeno-associated virus) vectors with specificity and high transduction efficiency for pancreatic alpha- and beta- islet cells.
Stanford researchers have invented a method and developed compositions of matter to reduce the production of infectious viruses in cells that line the respiratory tract. The invention enables the use of gene-silencing approaches to prevent and treat viral infections.
Stanford scientists have invented a new suite of adaptable hydrogel biomaterials that are optically transparent and injectable for cell encapsulation, tissue engineering, and drug delivery.
A major barrier in CAR-T cell therapies has been T cell exhaustion, which affects the durability and effectiveness of treatments, particularly for solid tumors.
The Hu Lab at Stanford has developed a neuroprotective gene therapy for treating glaucoma and other optic neuropathies. Their gene therapy AAV vector expresses NMNAT2 operably linked to a retinal ganglion cell-specific promoter (mSngc).
Researchers at Stanford have developed a methodology for deep learning-based image reconstruction by incorporating the physics or geometry priors of the imaging system with deep neural networks.
SparseGMM, is a new algorithm which is a novel statistical approach for identifying drug targets in cancer patients and other diseases by more accurately modeling biological pathways.
Stanford researchers have developed a novel approach to make a stable and active platinum-alumina catalyst that maintains high activity under harsh conditions.
Stanford researchers have developed a new controllable methodology for molecularly targeted ultrasound contrast agent production with pre-formed ligand-phospholipid bioconjugates.
Stanford researchers have developed an integrated printer/scanner platform to screen biofluids for bacterial pathogens and other cells of interest at the single cell level.